We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (SINTRA-REV)

This study is currently recruiting participants.
Verified April 2016 by Fundación General de la Universidad de Salamanca
Sponsor:
ClinicalTrials.gov Identifier:
NCT01243476
First Posted: November 18, 2010
Last Update Posted: April 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Fundación General de la Universidad de Salamanca
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2022
  Estimated Primary Completion Date: September 2021 (Final data collection date for primary outcome measure)